LSTA

MKT CAP:$29M

Lisata Therapeutics, Inc.

Market Cap

$29M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.33+$1.37 (+69.90%)

Apr 23, 2026

Company Details

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA...

CEO

David J. Mazzo

IPO Date

Mar 1, 1999

Website

www.lisata.com

Key Metrics TTM

Revenue

$170.0K

-83.0% YoY

Net Income

-$17M

EPS (Diluted)

-$1.91

Free Cash Flow

-$16M

Revenue / Share

$0.02

Gross Margin

91.2%

Operating Margin

-10711.2%

Net Margin

-9756.5%

FCF Margin

-9414.7%

P/S

171.1x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 12, 2026

$170.0K-83.0%EPS -$1.91

Q4 2025

Mar 12, 2026

$100.0K-90.0%EPS -$0.33

Q3 2025

Nov 6, 2025

$0EPS -$0.49

Q2 2025

Aug 7, 2025

$70.0KEPS -$0.54

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$7M
Q2 22	$0	$0	-$7M
Q3 22	$0	$0	-$38M
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$7M
Q2 23	$0	$0	-$7M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$6M
Q1 24	$0	$0	-$7M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$5M
Q4 24	$1M	$1M	-$5M
Q1 25	$0	$0	-$6M
Q2 25	$70.0K	$70.0K	-$5M
Q3 25	$0	$0	-$4M
Q4 25	$100.0K	$85.0K	-$3M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	24.5x	—
Q1 25	20.2x	—
Q2 25	23.7x	—
Q3 25	20.7x	—
Q4 25	100.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$6M	-$6M
Q2 22	-$5M	-$5M
Q3 22	-$4M	-$4M
Q4 22	-$6M	-$6M
Q1 23	-$8M	-$8M
Q2 23	-$4M	-$4M
Q3 23	-$4M	-$4M
Q4 23	-$4M	-$4M
Q1 24	-$7M	-$7M
Q2 24	-$5M	-$5M
Q3 24	-$3M	-$3M
Q4 24	-$5M	-$5M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$3M	-$3M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$235.0K
Q3 22	$24.0K
Q4 22	$26.0K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$28.0K
Q2 25	$28.0K
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-18.1%
Q2 22	—	-6.0%
Q3 22	—	+441.3%
Q4 22	—	-4.5%
Q1 23	—	+3.4%
Q2 23	—	+2.3%
Q3 23	—	-84.2%
Q4 23	—	-7.9%
Q1 24	—	-3.6%
Q2 24	—	-19.7%
Q3 24	—	-10.5%
Q4 24	—	-1.3%
Q1 25	—	-11.4%
Q2 25	—	-10.6%
Q3 25	—	-17.3%
Q4 25	-90.0%	-46.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$760.0K	—
Q2 22	$368.0K	—
Q3 22	$1M	—
Q4 22	$468.0K	—
Q1 23	$675.0K	—
Q2 23	$0	—
Q3 23	$307.0K	—
Q4 23	$473.0K	—
Q1 24	$454.0K	—
Q2 24	$237	—
Q3 24	$327.0K	—
Q4 24	$871.8K	87.2%
Q1 25	$530.0K	—
Q2 25	$239.0K	341.4%
Q3 25	$232.0K	—
Q4 25	$225.0K	225.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$3M	$3M
Q2 22	$3M	$3M
Q3 22	$34M	$4M
Q4 22	$3M	$3M
Q1 23	$3M	$4M
Q2 23	$3M	$4M
Q3 23	$3M	$3M
Q4 23	$3M	$3M
Q1 24	$3M	$3M
Q2 24	$3M	$3M
Q3 24	$3M	$3M
Q4 24	$3M	$3M
Q1 25	$3M	$3M
Q2 25	$2M	$3M
Q3 25	$2M	$2M
Q4 25	$1M	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$13M	$76M	$89M
Q2 22	$33M	$40M	$73M
Q3 22	$31M	$44M	$76M
Q4 22	$32M	$37M	$69M
Q1 23	$28M	$33M	$61M
Q2 23	$24M	$34M	$58M
Q3 23	$32M	$22M	$54M
Q4 23	$23M	$28M	$51M
Q1 24	$22M	$22M	$43M
Q2 24	$28M	$10M	$38M
Q3 24	$20M	$16M	$36M
Q4 24	$16M	$15M	$31M
Q1 25	$20M	$6M	$26M
Q2 25	$17M	$5M	$22M
Q3 25	$19M	$0	$19M
Q4 25	$16M	$0	$16M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	4M	+1.3%	+43.8%
Q2 22	4M	-0.0%	+1.7%
Q3 22	5M	+17.6%	+19.5%
Q4 22	5M	+4.6%	+24.6%
Q1 23	8M	+60.9%	+97.8%
Q2 23	8M	+0.4%	+98.7%
Q3 23	8M	+1.5%	+71.5%
Q4 23	8M	-0.0%	+64.0%
Q1 24	8M	+1.9%	+3.8%
Q2 24	8M	+0.2%	+3.6%
Q3 24	8M	+0.2%	+2.2%
Q4 24	8M	+0.1%	+2.3%
Q1 25	9M	+3.3%	+3.7%
Q2 25	9M	+0.0%	+3.6%
Q3 25	9M	+1.5%	+5.0%
Q4 25	9M	-0.6%	+4.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	27
Q2 22	$0	27
Q3 22	$0	27
Q4 22	$0	27
Q1 23	$0	27
Q2 23	$0	27
Q3 23	$0	27
Q4 23	$0	25
Q1 24	$0	25
Q2 24	$0	25
Q3 24	$0	25
Q4 24	$38.5K	26
Q1 25	$0	26
Q2 25	$2.7K	26
Q3 25	$0	26
Q4 25	$1	200K

Revenue / Employee